Xenon Pharmaceuticals Inc Asset Resilience Ratio
Xenon Pharmaceuticals Inc asset resilience ratio. Xenon Pharmaceuticals Inc (XENE) has an Asset Resilience Ratio of 35.63% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Xenon Pharmaceuticals Inc (XENE) total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Xenon Pharmaceuticals Inc (2013–2025)
Asset resilience ratio of Xenon Pharmaceuticals Inc from 2013 to 2025. This chart shows how Xenon Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. See Xenon Pharmaceuticals Inc free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Liquid Assets Composition Over Time
This chart breaks down Xenon Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see XENE asset base.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $349.72 Million | 35.63% |
| Total Liquid Assets | $349.72 Million | 35.63% |
Asset Resilience Insights
- Very High Liquidity: Xenon Pharmaceuticals Inc maintains exceptional liquid asset reserves at 35.63% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Xenon Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio
Compare Xenon Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
BB Biotech AG
SW:BION |
Biotechnology | 92.97% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 65.12% |
|
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488 |
Biotechnology | 4.57% |
|
Eupraxia Pharmaceuticals Inc
TO:EPRX |
Biotechnology | 25.13% |
|
Cabio Biotech Wuhan Co Ltd
SHG:688089 |
Biotechnology | 3.60% |
Xenon Pharmaceuticals Inc Asset Resilience Ratio by Year (2013–2025)
Xenon Pharmaceuticals Inc asset resilience ratio by year from 2013 to 2025. The table below shows the annual Asset Resilience Ratio data for Xenon Pharmaceuticals Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 35.63% | $349.72 Million | $981.67 Million | -25.04pp |
| 2024-12-31 | 60.67% | $484.19 Million | $798.14 Million | +9.94pp |
| 2023-12-31 | 50.73% | $489.44 Million | $964.80 Million | -20.19pp |
| 2022-12-31 | 70.92% | $534.85 Million | $754.15 Million | +5.17pp |
| 2021-12-31 | 65.75% | $376.09 Million | $572.01 Million | -4.02pp |
| 2020-12-31 | 69.77% | $131.99 Million | $189.19 Million | -9.18pp |
| 2019-12-31 | 78.95% | $116.60 Million | $147.70 Million | +36.84pp |
| 2018-12-31 | 42.11% | $51.55 Million | $122.43 Million | -8.15pp |
| 2017-12-31 | 50.26% | $23.18 Million | $46.12 Million | -19.46pp |
| 2016-12-31 | 69.72% | $47.05 Million | $67.49 Million | -- |
| 2015-12-31 | 0.00% | $0.00 | $63.95 Million | -- |
| 2014-12-31 | 13.74% | $12.02 Million | $87.42 Million | -7.04pp |
| 2013-12-31 | 20.79% | $11.33 Million | $54.49 Million | -- |
About Xenon Pharmaceuticals Inc
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizure… Read more